EUVIMEDEUVIMED entdecken
Multizentrische Studie

Peptide Receptor Radionuclide Therapy or Everolimus in Metastatic Neuroendocrine Tumors: The SeqEveRIV Study, a National Study from the French Group of Endocrine Tumors and Endocan–RENATEN Network

Aurelien Fosse, Julien Hadoux, Paul Girot, Amandine Beron, Pauline Afchain, Anne-Segolene Cottereau, Eric Baudin, Lawrence O Dierickx, Thierry Lecomte, Marine Perrier, Come Lepage, Karine Bouhier-Leporrier und 4 weitere

Journal of Nuclear Medicine · 2024

DOI: 10.2967/jnumed.123.267363 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Nuclear Medicine, 2024. Verfasst von Aurelien Fosse und 15 weiteren Autor:innen. Beteiligte Einrichtung: Service d'Oncologie Médicale, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; thomas.walter@chu-lyon.fr aurelien.fosse@hotmail.fr. Hauptthemen laut MEDLINE: Everolimus, Neuroendocrine Tumors, Neoplasm Metastasis, Octreotide. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Everolimus and peptide receptor radionuclide therapy (PRRT, 177Lu-DOTATATE) are 2 treatments recommended in guidelines for gastroenteropancreatic metastatic neuroendocrine tumors. However, the best treatment sequence remains unknown.

Methods

We designed a retrospective multicenter study that included patients from the national prospective database of the Groupe d'Étude des Tumeurs Endocrines who had been treated using everolimus and PRRT between April 2004 and October 2022. The primary aim was to compare the 2 treatments (everolimus and PRRT) in terms of efficacy and safety, and the secondary aim was to evaluate the sequences (PRRT followed by everolimus or everolimus followed by PRRT) based on overall progression-free survival (PFS) (PFS during first treatment + PFS during second treatment) in patients with metastatic neuroendocrine tumors.

Results

Both treatments were used for 84 patients. The objective response rate and median PFS were 5 (6.0%) and 16.1 mo (95% CI, 11.5-20.7 mo), respectively, under everolimus and 19 (22.6%) and 24.5 mo (95% CI, 17.7-31.3 mo), respectively, for PRRT. The safety profile was also better for PRRT. Median overall PFS was 43.2 mo (95% CI, 33.7-52.7 mo) for the everolimus-PRRT sequence and 30.6 mo (95% CI, 17.8-43.4 mo) for the PRRT-everolimus sequence (hazard ratio, 0.69; 95% CI, 0.39-1.24; P = 0.22).

Conclusion

PRRT was more effective and less toxic than everolimus. Overall PFS was similar between the 2 sequences, suggesting case-by-case discussion if the patient is eligible for both treatments, but PRRT should be used first when an objective response is needed or in frail populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EverolimusNeuroendocrine TumorsNeoplasm MetastasisOctreotideHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAdultReceptors, PeptideFranceOrganometallic CompoundsAged, 80 and overTreatment Outcome

Stichwörter der Autor:innen

everolimusmetastaticneuroendocrine tumorspeptide receptor radionuclide therapysequence

Substanzen

EverolimusOctreotideReceptors, Peptidelutetium Lu 177 dotatateOrganometallic Compounds

Autor:innen und Institutionen

  • Service d'Oncologie Médicale, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; thomas.walter@chu-lyon.fr aurelien.fosse@hotmail.fr.
  • Service de Médecine Nucléaire et de Cancérologie Endocrinienne, Institut Gustave-Roussy, Villejuif, France.
  • Service d'Hépatologie et Gastro-Entérologie, CH Loire Vendée Océan, La-Roche-Sur-Yon, France.
  • Service de Médecine Nucléaire, Hôpital Claude Huriez, CHU Lille, Lille, France.
  • Service d'Oncologie Médicale, Hôpital Saint-Antoine, Paris, France.
  • Service de Médecine Nucléaire, Hôpital Cochin, Université Paris Cité, Paris, France.

Zitieren

APA

Fosse, A., Hadoux, J., Girot, P., Beron, A., Afchain, P., Cottereau, A. S., Baudin, E., Dierickx, L. O., Lecomte, T., Perrier, M., Lepage, C., Bouhier-Leporrier, K., Goichot, B., Lachachi, B., Walter, T., & Durand, A. (2024). Peptide Receptor Radionuclide Therapy or Everolimus in Metastatic Neuroendocrine Tumors: The SeqEveRIV Study, a National Study from the French Group of Endocrine Tumors and Endocan–RENATEN Network. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.123.267363

Vancouver

Fosse A, Hadoux J, Girot P, Beron A, Afchain P, Cottereau AS, et al. Peptide Receptor Radionuclide Therapy or Everolimus in Metastatic Neuroendocrine Tumors: The SeqEveRIV Study, a National Study from the French Group of Endocrine Tumors and Endocan–RENATEN Network. Journal of Nuclear Medicine. 2024. doi:10.2967/jnumed.123.267363

BibTeX
@article{Fosse2024,
  author = {Fosse, Aurelien and Hadoux, Julien and Girot, Paul and Beron, Amandine and Afchain, Pauline and Cottereau, Anne-Segolene and Baudin, Eric and Dierickx, Lawrence O and Lecomte, Thierry and Perrier, Marine and Lepage, Come and Bouhier-Leporrier, Karine and Goichot, Bernard and Lachachi, Boumediene and Walter, Thomas and Durand, Alice},
  title = {Peptide Receptor Radionuclide Therapy or Everolimus in Metastatic Neuroendocrine Tumors: The SeqEveRIV Study, a National Study from the French Group of Endocrine Tumors and Endocan–RENATEN Network},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  doi = {10.2967/jnumed.123.267363}
}
Kostenlos starten →